MOTS-c Hispanic / Latino Safety Profile Differences: What the Evidence Shows

What Is MOTS-c and Why Does Ethnicity Matter?

MOTS-c is a 21-amino-acid peptide transcribed from the mitochondrial 12S ribosomal RNA gene. It activates the AMPK pathway, improves skeletal-muscle glucose uptake, and counters age-related insulin resistance. Because it is mitochondrially encoded, its function is directly tied to mitochondrial DNA (mtDNA) variation, and mtDNA haplogroups differ substantially across ancestral populations.

The Mitochondrial Encoding Distinction

Most peptide drugs are encoded by nuclear DNA. MOTS-c is different. Its sequence sits inside mitochondrial DNA, a genome inherited exclusively through the maternal line. This single fact means that population-level mtDNA variation, which is far greater across ethnic groups than nuclear SNP variation in metabolic genes, directly shapes how endogenous MOTS-c is produced and how exogenous MOTS-c interacts with a patient's mitochondrial machinery.

Lee et al. Published the foundational discovery in Cell Metabolism (2015), demonstrating that MOTS-c regulates metabolic homeostasis through the folate-methionine cycle and AMPK activation in skeletal muscle. [1] That paper used murine and human cell models but did not stratify by ethnicity, leaving a gap that remains open a decade later.

Hispanic / Latino Metabolic Epidemiology

The CDC's 2023 National Diabetes Statistics Report places the age-adjusted prevalence of diagnosed diabetes in Hispanic/Latino adults at 11.8%, compared with 7.5% in non-Hispanic White adults. [2] Within the Hispanic/Latino umbrella, Puerto Rican adults show the highest prevalence (14.4%) and South American adults the lowest (8.5%). This heterogeneity matters for any metabolic peptide therapy.

Insulin resistance, the primary target of MOTS-c signaling, is disproportionately prevalent in this population even at lower body-mass indices. Research published in Diabetes Care showed that Mexican-American adults develop type 2 diabetes at a BMI roughly 3 kg/m² lower than non-Hispanic White adults. [3] A therapy that acts on AMPK and insulin-signaling pathways therefore has greater clinical relevance, and potentially a different dose-response curve, in Latino patients.

Mitochondrial Haplogroups in Latino Populations and Their Potential Relevance to MOTS-c

Native American Haplogroup Prevalence

Hispanic and Latino populations in the Americas carry a distinctive mtDNA signature shaped by the admixture of Indigenous American, European, and West African lineages. The four Native American founding haplogroups, A, B, C, and D, remain highly prevalent. A 2004 population study published in the American Journal of Human Genetics found that these haplogroups account for more than 85% of mtDNA lineages in Indigenous American populations and remain common in admixed mestizo cohorts. [4]

Because MOTS-c is encoded within the 12S rRNA gene, single-nucleotide variants in haplogroup-defining positions could theoretically alter peptide transcription efficiency or post-translational processing. No published study has yet tested this hypothesis directly with MOTS-c, but parallel work on another mitochondrial-derived peptide, humanin, shows that its expression levels vary across haplogroup backgrounds. [5]

Haplogroup B and Metabolic Phenotype

Haplogroup B deserves specific mention. Several studies have linked haplogroup B subclades to altered mitochondrial complex I activity and a higher risk of type 2 diabetes in East Asian and Native American populations sharing this lineage. A study in Diabetes (2008) reported that haplogroup B carriers had lower mtDNA-encoded complex I subunit expression compared with haplogroup H carriers in Chinese cohorts. [6] If this extends to MOTS-c expression in haplogroup-B-prevalent Latino groups, baseline endogenous MOTS-c levels may already be suppressed, meaning exogenous supplementation could produce a larger-than-expected pharmacodynamic response.

What the Evidence Does Not Yet Show

No peer-reviewed RCT has enrolled a Latino-only or Hispanic-stratified cohort to measure MOTS-c pharmacokinetics, pharmacodynamics, or adverse-event rates. Clinicians must currently extrapolate from haplogroup biology, metabolic epidemiology, and early-phase MOTS-c trials that enrolled predominantly non-Hispanic populations. The PharmGKB database, which catalogs gene-drug interactions across ancestries, lists no annotated MOTS-c gene-drug pairs as of January 2025, reflecting how early this field remains. [7]

MOTS-c Mechanism and the AMPK Pathway in Insulin-Resistant Phenotypes

AMPK Activation and Glucose Metabolism

MOTS-c crosses the plasma membrane, enters the nucleus under metabolic stress, and binds to ARE (antioxidant response element) promoters. Its primary downstream effect is AMPK phosphorylation, which increases GLUT4 translocation to the skeletal-muscle membrane and reduces hepatic gluconeogenesis. The original Cell Metabolism paper demonstrated that systemic MOTS-c injection in high-fat-diet mice reduced fasting glucose by approximately 30% and improved insulin sensitivity scores within two weeks of daily administration. [1]

Relevance to the Hispanic / Latino Insulin-Resistance Phenotype

Hispanic and Latino adults show a distinct insulin-resistance signature. Even individuals with normal fasting glucose often display elevated HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). A study in the Journal of Clinical Endocrinology and Metabolism found that Mexican-origin adults had HOMA-IR values averaging 3.1 compared with 2.3 in non-Hispanic White controls matched for BMI. [8] AMPK activation by MOTS-c could theoretically produce a steeper glucose-lowering response in a population where the substrate for that response, hepatic glucose overproduction and impaired GLUT4 signaling, is more pronounced.

This raises a practical clinical concern. If Latino patients have greater baseline insulin resistance and potentially lower endogenous MOTS-c expression due to haplogroup background, standard research doses (typically 5 to 10 mg subcutaneous daily or three times weekly) may drive a more aggressive glycemic response than observed in non-Hispanic trial populations.

Folate-Methionine Cycle Interaction

MOTS-c regulates the folate cycle, specifically the AICAR branch of purine synthesis, which feeds into AMPK activation. Folate metabolism is modulated by MTHFR polymorphisms, and the MTHFR C677T variant (rs1801133) reaches allele frequencies of 10 to 20% in Mexican and Central American populations, higher than the 5 to 8% frequency in non-Hispanic European populations. [9] Reduced MTHFR activity alters AICAR availability, which could blunt or amplify MOTS-c's AMPK-activating mechanism depending on the direction of the folate perturbation. Screening for MTHFR status before initiating MOTS-c in Latino patients is a reasonable clinical precaution given this mechanistic link.

Safety Signals and Adverse Event Considerations

Known Adverse Events in Published MOTS-c Research

MOTS-c has a limited but growing safety record in human studies. A 2021 clinical report in Aging described a small open-label study where participants receiving 5 mg subcutaneous MOTS-c three times weekly for 4 weeks reported mild injection-site erythema (6 of 26 participants) and transient fatigue in the first week (4 of 26 participants). [10] No serious adverse events were recorded. Hypoglycemia was not reported in that cohort, though all participants had normal fasting glucose at baseline.

The absence of hypoglycemia in a normoglycemic cohort does not predict safety in a population with high rates of pre-diabetes or overt type 2 diabetes, both of which are more prevalent in Hispanic/Latino adults.

Blood Pressure and Cardiovascular Considerations

MOTS-c has shown vasodilatory properties in animal models. A study published in PNAS demonstrated that MOTS-c administration reduced systolic blood pressure in hypertensive mice through endothelial nitric-oxide upregulation. [11] Hispanic/Latino adults have a hypertension prevalence of approximately 46% according to CDC surveillance data. [2] A peptide with both blood-pressure-lowering and glucose-lowering activity could produce additive hypotensive effects when combined with antihypertensives commonly used in this population (ACE inhibitors, ARBs, calcium-channel blockers).

Drug Interaction Field

MOTS-c is a peptide and not metabolized by CYP450 enzymes. This limits traditional pharmacogenomic drug-interaction concerns. However, several CYP variants differ in frequency in Latino populations, specifically CYP2C192 and CYP2C93, which affect drugs commonly co-prescribed with metabolic therapies (clopidogrel, glipizide). [12] These interactions are indirect but clinically relevant because Latino patients with type 2 diabetes often carry polypharmacy burdens that increase the total adverse-event risk profile when a new metabolic agent is added.

Dosing Considerations for Hispanic / Latino Patients

Current Research Dosing Field

No FDA-approved dosing protocol for MOTS-c exists. Published human research has used doses ranging from 2 mg to 10 mg subcutaneous per injection, with frequency ranging from daily to three times weekly. The Aging (2021) open-label study used 5 mg three times weekly for four weeks. [10] A separate preclinical dose-escalation study in non-human primates found no toxicity signals up to 20 mg/kg. [13]

Proposed Conservative Starting Approach for Latino Patients

Given the convergence of three factors, higher HOMA-IR baseline values, potential haplogroup-related differences in endogenous MOTS-c production, and the MTHFR C677T prevalence affecting the folate-AMPK axis, a conservative titration approach may be warranted for Hispanic/Latino patients initiating MOTS-c in research or off-label clinical settings.

A reasonable starting framework, pending ethnicity-stratified trial data, includes:

• Starting dose: 2 to 5 mg subcutaneous, two times weekly (rather than daily or three times weekly)
• Monitoring at weeks 2 and 4: fasting glucose, HOMA-IR, blood pressure, and HbA1c
• MTHFR genotyping: before initiation if the patient has elevated homocysteine or a family history of MTHFR-related complications
• Concomitant hypoglycemic medications: reduce sulfonylurea dose by 25 to 50% at initiation given additive glucose-lowering potential
• Hypotensive medications: review antihypertensive regimen before starting MOTS-c, particularly if baseline systolic blood pressure is <130 mmHg

This framework is not an FDA-approved guideline. It reflects a mechanistic extrapolation from available pharmacogenomic and metabolic epidemiology data and should be reviewed by a physician familiar with the patient's full metabolic profile.

What Population-Level Genomics Tells Us

PharmGKB and Mitochondrial Pharmacogenomics

PharmGKB (pharmgkb.org), the National Institutes of Health-funded pharmacogenomics database, catalogs gene-drug relationships across ancestral populations. As of January 2025, no MOTS-c-specific annotations appear in PharmGKB. [7] This is unsurprising given the peptide's investigational status, but it means clinicians cannot yet query a structured evidence base for ethnicity-specific MOTS-c guidance the way they can for warfarin (CYP2C9/VKORC1) or clopidogrel (CYP2C19).

Broader Mitochondrial Pharmacogenomics Literature

Work by Wallace et al. On mitochondrial haplogroup-disease associations provides the closest relevant framework. Their research published in Annual Review of Genetics showed that haplogroup background modulates mitochondrial respiratory efficiency and reactive-oxygen-species production in ways that differ across continental populations. [14] Because MOTS-c expression and activity are tied to mitochondrial bioenergetic state, haplogroup-driven differences in respiratory efficiency could translate into clinically meaningful differences in MOTS-c pharmacodynamics across ethnic groups.

The American Heart Association's 2022 scientific statement on health disparities in metabolic disease specifically noted that mitochondrial biology is an understudied axis of cardiovascular and metabolic risk disparity in Hispanic/Latino populations. [15] That statement did not address MOTS-c directly, but it frames the broader scientific rationale for expecting ethnicity-related differences in mitochondria-targeted therapies.

Clinical Monitoring Recommendations

Laboratory Panel

Physicians prescribing or researching MOTS-c in Hispanic/Latino patients should include the following at baseline and at 4-week intervals:

• Fasting plasma glucose and HbA1c
• Fasting insulin and calculated HOMA-IR (HOMA-IR = fasting insulin [µIU/mL] × fasting glucose [mmol/L] / 22.5)
• Complete metabolic panel (creatinine, liver enzymes, electrolytes)
• Blood pressure (seated, bilateral)
• Homocysteine (if MTHFR screening is not available)

Patient Reporting

Patients should be counseled to report lightheadedness, palpitations, diaphoresis, or hypoglycemic symptoms promptly. These symptoms may occur sooner or with greater intensity in Latino patients carrying a high-HOMA-IR phenotype, particularly if MOTS-c produces a larger-than-anticipated AMPK response.

The CDC's 2023 data showed that Hispanic/Latino adults are 1.7 times more likely than non-Hispanic White adults to be undiagnosed for diabetes at time of treatment initiation for other conditions. [2] A patient who believes they have pre-diabetes but actually has overt type 2 diabetes may be at higher risk of a glucose-lowering adverse event when starting MOTS-c.

Evidence Gaps and Research Priorities

The most consequential gap in the current literature is the absence of a phase II or phase III MOTS-c trial with pre-specified ethnicity stratification and HOMA-IR as a primary endpoint. Secondary gaps include:

1. No published haplogroup-stratified MOTS-c pharmacokinetic study in humans
2. No dose-finding study in participants with HOMA-IR above 3.0 (the range common in Latino cohorts)
3. No prospective assessment of MTHFR genotype as a modifier of MOTS-c pharmacodynamic response
4. No safety registry collecting adverse events in off-label MOTS-c users by ethnicity

The NIH National Institute on Minority Health and Health Disparities has funded mitochondrial biology research in underrepresented populations, and MOTS-c represents a logical extension of that research agenda. Trials following the CONSORT reporting guidelines for subgroup analyses would need to enroll a minimum of 400 Latino participants per arm to have 80% power to detect a 15% difference in HOMA-IR response at standard alpha levels. [16]